0001164888 false Q2 --03-31 2022 0001164888 2021-04-01 2021-09-30 0001164888 2021-11-15 0001164888 2021-09-30 0001164888 2021-03-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 2021-07-01 2021-09-30 0001164888 2020-07-01 2020-09-30 0001164888 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2021-06-30 0001164888 KBPH:PreferredStockBMember 2021-06-30 0001164888 us-gaap:CommonStockMember 2021-06-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001164888 us-gaap:RetainedEarningsMember 2021-06-30 0001164888 2021-06-30 0001164888 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-07-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 KBPH:PreferredStockBMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001164888 us-gaap:RetainedEarningsMember 2021-03-31 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-04-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2020-06-30 0001164888 KBPH:PreferredStockBMember 2020-06-30 0001164888 us-gaap:CommonStockMember 2020-06-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001164888 us-gaap:RetainedEarningsMember 2020-06-30 0001164888 2020-06-30 0001164888 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-07-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-09-30 0001164888 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 KBPH:PreferredStockBMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001164888 us-gaap:RetainedEarningsMember 2020-03-31 0001164888 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-04-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-04-01 2020-09-30 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSidecarTwentyFivePercentageDiscountNoInterestMember 2021-09-30 0001164888 KBPH:AOADXIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AOADXIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:EveryKeyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IdenticalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KianaAnalyticsMember KBPH:TechnologyMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageNoDueDateMember 2021-09-30 0001164888 KBPH:MMTronIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:MMTronIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NavauxIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-04-01 2021-09-30 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-09-30 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-04-01 2021-09-30 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-09-30 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-09-30 0001164888 KBPH:SinglePassIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SinglePassIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:CorporateNoteSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-04-01 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-04-01 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:PromaxolIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SanabyHealthSponsorLLCMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:SanabyHealthSponsorLLCMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockInvestmentMember 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember 2021-09-30 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-09-30 0001164888 KBPH:MadorraIncMember KBPH:SafeInvestmentsMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:PolymertalIncMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:SafeInvestmentsMember 2021-09-30 0001164888 KBPH:SafeInvestmentsMember country:US 2021-09-30 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-09-30 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:OtherInvestmentMember 2021-09-30 0001164888 KBPH:OtherInvestmentMember country:US 2021-09-30 0001164888 KBPH:OtherInvestmentMember country:CA 2021-09-30 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-09-30 0001164888 country:US 2021-09-30 0001164888 country:CA 2021-09-30 0001164888 KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-03-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2020-04-01 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-03-31 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-03-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2020-04-01 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-03-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:PromaxoMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:PromaxoMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2020-04-01 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember country:US 2021-03-31 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2020-04-01 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-03-31 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-03-31 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember country:US 2021-03-31 0001164888 KBPH:OtherInvestmentMember country:CA 2021-03-31 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-03-31 0001164888 country:US 2021-03-31 0001164888 country:CA 2021-03-31 0001164888 KBPH:RestOfWorldMember 2021-03-31 0001164888 2018-03-31 0001164888 srt:MaximumMember 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-01-02 0001164888 srt:ChiefExecutiveOfficerMember 2021-05-01 2021-05-31 0001164888 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2021-04-01 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2020-04-01 2020-09-30 0001164888 2021-10-01 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-07-01 2021-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-07-01 2020-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-04-01 2021-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-04-01 2020-09-30 0001164888 KBPH:CommonStockIssuedMember 2021-07-01 2021-09-30 0001164888 KBPH:CommonStockIssuedMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockSubscribedNotIssuedMember 2021-07-01 2021-09-30 0001164888 KBPH:CommonStockSubscribedNotIssuedMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2021-04-01 2021-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockIssuedMember 2020-07-01 2020-09-30 0001164888 KBPH:CommonStockIssuedMember 2020-04-01 2020-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2020-07-01 2020-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2020-04-01 2020-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2020-07-01 2020-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2020-04-01 2020-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:SafeMember 2021-09-30 0001164888 KBPH:SafeMember 2021-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2021-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-07-01 2021-09-30 0001164888 srt:WeightedAverageMember KBPH:PromaxoIncMember KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-07-01 2021-09-30 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-07-01 2021-09-30 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2021-03-31 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-03-31 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001164888 country:US 2021-04-01 2021-09-30 0001164888 country:CA 2021-04-01 2021-09-30 0001164888 KBPH:RestOfWorldMember 2021-04-01 2021-09-30 0001164888 country:US 2020-03-31 0001164888 country:CA 2020-03-31 0001164888 KBPH:RestOfWorldMember 2020-03-31 0001164888 country:US 2020-04-01 2020-09-30 0001164888 country:CA 2020-04-01 2020-09-30 0001164888 KBPH:RestOfWorldMember 2020-04-01 2020-09-30 0001164888 country:US 2020-09-30 0001164888 country:CA 2020-09-30 0001164888 KBPH:RestOfWorldMember 2020-09-30 0001164888 KBPH:FintechMember 2021-03-31 0001164888 KBPH:TechnologyMember 2021-03-31 0001164888 KBPH:LifeScienceMember 2021-03-31 0001164888 KBPH:FintechMember 2021-04-01 2021-09-30 0001164888 KBPH:TechnologyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifeScienceMember 2021-04-01 2021-09-30 0001164888 KBPH:FintechMember 2021-09-30 0001164888 KBPH:TechnologyMember 2021-09-30 0001164888 KBPH:LifeScienceMember 2021-09-30 0001164888 KBPH:FintechMember 2020-03-31 0001164888 KBPH:TechnologyMember 2020-03-31 0001164888 KBPH:LifeScienceMember 2020-03-31 0001164888 KBPH:FintechMember 2020-04-01 2020-09-30 0001164888 KBPH:TechnologyMember 2020-04-01 2020-09-30 0001164888 KBPH:LifeScienceMember 2020-04-01 2020-09-30 0001164888 KBPH:FintechMember 2020-09-30 0001164888 KBPH:TechnologyMember 2020-09-30 0001164888 KBPH:LifeScienceMember 2020-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-04-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SafeMember 2021-04-01 2021-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 KBPH:SafeMember 2020-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2020-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001164888 KBPH:SafeMember 2020-04-01 2020-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2020-04-01 2020-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 KBPH:SafeMember 2020-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2020-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-09-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAOneAndSeriesATwoPreferredStockMember us-gaap:IPOMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesATwoPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember us-gaap:SeriesBPreferredStockMember 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOneAndSeriesBTwoPreferredStockMember us-gaap:IPOMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBTwoPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-09-29 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-07-01 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-03-31 0001164888 KBPH:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2018-04-28 2018-04-30 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-31 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-29 2019-07-31 0001164888 KBPH:TwoThousandAndTwentyStockOptionAndIncentivePlanMember 2020-12-31 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-07-01 2021-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-07-01 2020-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-04-01 2021-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-04-01 2020-09-30 0001164888 srt:MinimumMember 2021-03-31 0001164888 srt:MaximumMember 2021-03-31 0001164888 srt:MinimumMember 2021-04-01 2021-09-30 0001164888 srt:MaximumMember 2021-04-01 2021-09-30 0001164888 srt:MinimumMember 2020-04-01 2021-03-30 0001164888 srt:MaximumMember 2020-04-01 2021-03-30 0001164888 2020-04-01 2021-03-30 0001164888 us-gaap:WarrantMember 2020-03-31 0001164888 us-gaap:WarrantMember 2020-04-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-09-30 0001164888 us-gaap:WarrantMember 2019-04-01 2020-03-31 0001164888 us-gaap:WarrantMember 2021-03-31 0001164888 us-gaap:WarrantMember 2021-04-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-09-30 0001164888 us-gaap:WarrantMember 2020-04-01 2021-03-31 0001164888 2021-01-01 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember us-gaap:SubsequentEventMember 2021-10-05 0001164888 us-gaap:SubsequentEventMember KBPH:SeriesBThreePreferredStockMember 2021-11-12 2021-11-13 0001164888 us-gaap:SubsequentEventMember 2021-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure KBPH:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the transition period from: _____________ to _____________

 

KYTO TECHNOLOGY AND LIFE SCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

delaware   000-50390   65-1086538
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)

 

13050 Paloma Road, Los Altos Hills, CA 94022

(Address of Principal Executive Office) (Zip Code)

 

(650) 204 7896

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Title of each class   Trading Symbol   Exchange
Common stock   KBPH   OTC QB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (ss. 232.405 of this chapter) during the preceding 12 (or for such shorter period that the registrant was required to submit such files). ☒ Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer Accelerated filer
  Non-accelerated filer Smaller reporting company
  Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

13,287,621 Common Shares - $.01 Par Value - as of November 15, 2021

 

 

 

 

 

 

KYTO Technology and Life Science, Inc.

For the quarterly period ended September 30, 2021

 

INDEX

 

  PART I. FINANCIAL INFORMATION  
     
Item 1. Financial Statements 3
     
  Condensed Statements of Asset and Liabilities as of September 30, 2021 (Unaudited) and March 31, 2021 3
     
  Unaudited Condensed Statements of Operations for the Three Months and Six Months Ended September 30, 2021 and 2020 4
     
  Unaudited Condensed Statements of Changes in Net Assets for the Three Months and Six Months Ended September 30, 2021 and 2020 5
     
  Unaudited Condensed Statements of Cash Flows for the Six Months Ended September 30, 2021 and 2020 7
     
  Condensed Schedule of Investments as of September 30, 2021 (Unaudited) and March 31, 2021 9
     
  Notes to Unaudited Interim Condensed Financial Statements 14
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 28
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 32
     
Item 4. Controls and Procedures. 32
     
  PART II. OTHER INFORMATION  
     
Item 1. Legal Proceedings. 33
     
Item 1A. Risk Factors. 33
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 33
     
Item 3. Defaults Upon Senior Securities. 33
     
Item 4. Mine Safety Disclosures 33
     
Item 5. Other Information 33
     
Item 6. Exhibits 33
     
  Signatures 35

 

2

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

Kyto Technology and Life Science, Inc.

Condensed Statements of Assets and Liabilities

 

   September 30,   March 31, 
   2021   2021 
   (Unaudited)     
ASSETS          
Investments at fair value (cost of $7,904,636 and $5,686,545, respectively)  $10,442,813   $6,821,407 
Cash   316,124    1,437,868 
Other current assets   230,434    169,891 
Total Assets  $10,989,371   $8,429,166 
           
LIABILITIES          
           
Liabilities          
Accounts payable and accrued liabilities  $84,477   $193,141 
Accrued liabilities - related parties   87,000    51,420 
Common stock subscription liability   -    1,191,442 
Total Liabilities   171,477    1,436,003 
           
Commitments and Contingencies (Note 3)   -    - 
           
           
Net Assets          
Preferred stock authorized but not designated, $.01 par value 19,800,000 shares, none issued and outstanding as of September 30, 2021 and March 31, 2021, respectively   -    - 
Series A (including Series A-1 and A-2) preferred convertible stock, $0.01 par value, 4,200,000 shares designated, 4,200,000 issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,720,000 at September 30, 2021 and March 31, 2021, respectively   42,001    42,001 
Series B (including Series B-1 and B-2) preferred convertible stock, $0.01 par value, 6,000,000 shares designated, 5,911,406 and 3,628,906 issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $9,458,250 at September 30, 2021 and $5,806,250 at March 31, 2021, respectively   59,114    36,289 
Common stock, $.01 par value, 40,000,000 shares authorized, 13,287,621 and 9,983,082 issued and outstanding as of September 30, 2021 and March 31 2021, respectively   132,876    99,831 
Additional paid-in capital   42,878,748    39,772,228 
Accumulated deficit   (32,294,845)   (32,957,186)
           
Total Net Assets   10,817,894    6,993,163 
           
Total Liabilities and Net Assets  $10,989,371   $8,429,166 

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

3

 

 

Kyto Technology and Life Science, Inc.

Condensed Statements of Operations

(Unaudited)

 

   2021   2020   2021   2020 
   For the Three months ended
September 30,
   For the Six months ended
September 30,
 
   2021   2020   2021   2020 
INVESTMENT INCOME                    
                     
Interest and other income  $-   $-   $-   $500 
                     
Total investment income   -    -    -    500 
                     
EXPENSES                    
Professional fees   107,201    63,605    273,359    76,543 
Other operating expenses   245,519    96,506    466,027    122,936 
Interest and non operating expenses   1,596    -    1,588    - 
Total expenses   354,316    160,111    740,974    199,479 
                     
Net investment loss   (354,316)   (160,111)   (740,974)   (198,979)
                     
Net change in unrealized gain from investments   1,350,449    478,248    1,403,315    478,248 
                     
Net increase in net assets resulting from operations  $996,133   $318,137   $662,341   $279,269 
                     
Basic earnings per Common Share,                    
Net increase in net assets resulting from operations per common share  $0.08   $0.05   $0.05   $0.05 
                     
Weighted average common shares outstanding   13,271,996    5,836,832    13,269,764    5,836,832 
                     
Fully-diluted earnings per Common Share,                    
Net increase in net assets resulting from operations per common share  $0.04   $0.02   $0.03   $0.02 
                     
Weighted average common shares outstanding   27,338,695    17,987,040    26,263,218    17,058,856 

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

4

 

 

Kyto Technology and Life Science, Inc.

 

Condensed Statements of Changes in Net Assets for the Three and Six months ended September 30, 2021

( Unaudited)

 

       Preferred A      Preferred B       Common   Additional         
   Preferred A (Including Series A-1, A-2)  

Preferred A

Stock (Including Series A-1, A-2)

   Preferred B (Including Series B-1, B-2)  

Preferred B (Including Series B-1, B-2)

Stock
   Common  

Common

Stock

  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Three months ended September 30, 2021                                             
Balance, June 30, 2021   4,200,000   $42,001    4,320,156   $43,202    13,268,871   $132,689   $41,610,332   $(33,290,978)  $8,537,246 
Net increase in net assets resulting from operations                                      996,133    996,133 
Sale of Series B-1 Preferred stock at $0.80 per share   -     -     1,591,250    15,912              1,257,088         1,273,000 
Exercise of stock options                       18,750    187    431         618 
Compensation expense from stock options                                 10,897         10,897 
                                              
Balance, September 30, 2021   4,200,000   $42,001    5,911,406   $59,114   13,287,621  $132,876   $42,878,748   $(32,294,845)  $10,817,894 
                                              
Six months ended September 30, 2021                                             
Balance, March 31, 2021   4,200,000   $42,001    3,628,906   $36,289    9,983,082   $99,831   $39,772,228   $(32,957,186)  $6,993,163 
Net increase in net assets resulting from operations                                      662,341    662,341 
Sale of Series B-1 Preferred stock at $0.80 per share   -     -     2,282,500    22,825              1,803,176         1,826,001 
Sale of common stock at $0.40 per share                       3,285,789    32,858    1,281,459         1,314,317 
Exerrcise of stock options                       18,750    187    431         618 
Compensation expense from stock options                                 21,454         21,454 
                                              
Balance, September 30, 2021   4,200,000   $42,001    5,911,406   $59,114   13,287,621  $132,876   $42,878,748   $(32,294,845)  $10,817,894 

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

5

 

 

Kyto Technology and Life Science, Inc.

 

Condensed Statements of Changes in Net Assets for the Three and Six months ended September 30, 2020

( Unaudited)

 

   Preferred A   

Preferred A

Stock

   Preferred B   

Preferred B

Stock

   Common  

Common

Stock

  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
                                                                                                                                             
Three months ended September 30, 2020                                             
Balance, June 30, 2020   42,000,000   $42,001    1,281,250   $12,188    5,836,832   $58,368   $36,315,354   $(33,423,120)  $3,004,791 
Net increase in net assets resulting from operations   -    -    -    -    -    -    -    318,137    318,137 
Sale of Series B Preferred stock at $0.80 per share   -    -    1,056,250    11,187    -    -    883,813    -    895,000 
Compensation expense from stock options   -    -    -    -    -    -    12,803    -    12,803 
                                              
Balance, September 30, 2020   42,000,000   $42,001    2,337,500   $23,375   5,836,832  $58,368   $37,211,970   $(33,104,983)  $4,230,731 
                                              
Six months ended September 30, 2020                                             
Balance, March 31, 2020   42,000,000   $42,001    812,500   $8,125    5,836,832   $58,368   $35,943,369   $(33,384,252)  $2,667,611 
Net increase in net assets resulting from operations   -    -    -    -    -    -    -    279,269    279,269 
Sale of Series B Preferred stock at $0.80 per share   -    -    1,525,000    15,250    -    -    1,254,750    -    1,270,000 
Compensation expense from stock options   -    -    -    -    -    -    13,851    -    13,851 
                                              
Balance, September 30, 2020   42,000,000   $42,001    2,337,500   $23,375   5,836,832  $58,368   $37,211,970   $(33,104,983)  $4,230,731 

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

6

 

 

Kyto Technology and Life Science, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

   2021   2020 
  

Six months months ended

September 30,

 
   2021   2020 
         
Operating activities:          
Net increase in net assets resulting from operations  $662,341   $279,269 
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash used in operating activities          
Net change in unrealized gain on investments   (1,403,315)   (478,248)
Stock option compensation expense   21,454    13,851 
Change in operating assets and liabilities          
Other current assets   (60,543)   500 
Accounts payable and accrued liabilities   (108,664)   15,064 
Accrued liabilities to related parties   35,580    - 
Purchase of investments   (2,218,091)   (740,000)
Net cash used in operating activities   (3,071,238)   (909,564)
           
Cash flows from financing activities:          
Sale of Common stock in connection with preference rights (see Note 6)   122,875    - 
Sale of Common stock from exercise of options stock   618    - 
Sale of Series B-1 Preferred stock   1,826,001    1,270,000 
Receipt of SBA loan   -    1,000 
Advances from related party   -    2,250 
Net cash provided by financing activities   1,949,494    1,273,250 
           
Net increase/(decrease) in cash   (1,121,744)   363,686 
Cash, beginning of period   1,437,868    33,756 
           
Cash, end of period  $316,124   $397,442 
           
Supplemental cash flow information          
Interest paid  $1,588   $- 
Taxes paid  $800   $800 
Supplemental schedule of noncash financing activities:          
Conversion of common stock subscription liability to common stock  $1,191,442   $- 

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

7

 

 

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of September 30, 2021

(Unaudited)

 

   Portfolio Company    Industry  Investment  Cost   Fair value   % of net assets (a) 
Convertible loan investments                       
   Abfero Pharmaceuticals Inc    Life science  Convertible Note, 6% due, December 2022  $100,000   $102,630    0.9%
( i )  Achelios Therapeutics Inc.    Life science  Convertible Note, 8% due, December 2021   100,000    125,184    1.2%
( i )  Achelios Therapeutics Inc.    Life science  Convertible Note, 8% due December 2021   25,000    30,036    0.3%
( i )  Achelios Therapeutics Inc.    Life science  Convertible Note, 8% due December 2021   50,000    56,586    0.5%
( i )  Achelios Therapeutics Inc.    Life science  Convertible Note Sidecar, 25% discount. No interest   50,000    50,000    0.5%
   AOA DX Inc    Life science  Convertible Note, 4%, due May 2024   100,000    101,567    0.9%
   Avisi Technologies Inc    Life science  Convertible Note, 8% due July 2022   50,000    54,679    0.5%
   Basepaws Inc    Life science  Convertible Note, 1% due April 2020   50,000    201,663    1.9%
( i )  Beam Semiconductor Inc  *   Technology  Convertible Note, 8% due April 2022   150,000    177,058    1.6%
( i )  Beam Semiconductor Inc  *   Technology  Convertible Note, 8% due March 2021   50,000    56,290    0.5%
( i )  Beam Semiconductor Inc  *   Technology  Convertible Note, 8% due March 2022   100,000    103,704    1.0%
   CoLabs Inc    Life science  Convertible Note, 6% due February 2023   50,000    50,304    0.5%
   Corinnova Inc    Life science  Convertible Note, 6% due December 2024   100,000    105,211    1.0%
   Corinnova Inc    Life science  Convertible Note, 6% due December 2024   50,000    50,164    0.5%
  Cyberdontics Inc  *   Life science  Convertible Note, 8% due September 2022   30,000    34,971    0.3%
  Cyberdontics Inc  *   Life science  Convertible Note, 8% due February 2023   35,000    39,457    0.4%
  Cyberdontics Inc  *   Life science  Convertible Note, 0% no due date   35,000    37,700    0.3%
   Deep Blue Medical Advances Inc    Life science  Convertible Note, 6% due June 2022   50,000    52,351    0.5%
   Every Key Inc    Technology  Convertible Note, 5% due December 2023   100,000    109,027    1.0%
   Identical Inc    Life science  Convertible Note, 2% due May 2022   100,000    101,775    0.9%
   INBay Technology Inc     Technology  Convertible Note, 12% due October 2020   50,000    67,589    0.6%
   INBay Technology Inc     Technology  Convertible Note, 12% due July 2021   30,000    38,028    0.4%
   INBay Technology Inc     Technology  Convertible Note, 12% due February 2022   50,000    59,649    0.6%
   INBay Technology Inc     Technology  Convertible Note, 12% due December 2022   40,000    43,958    0.4%
   INBay Technology Inc     Technology  Convertible Note, 12% due December 2023   50,000    52,926    0.5%
   Iris R&D Group Inc     Technology  Convertible Note, 8% May 2023   50,000    51,447    0.5%
   Kiana Analytics Inc    Technology  Convertible Note, 3% December 2022   100,000    102,326    0.9%
   Kitotech Medical Inc    Life science  Convertible Note, 6% due December 2020   100,000    246,141    2.3%
   Kitotech Medical Inc    Life science  Convertible Note, 6% due November 2022   75,000    85,896    0.8%
   Lifewave Biomedical Inc    Life science  Convertible Note, 6% due December 2020   30,000    33,733    0.3%
   Lifewave Biomedical Inc    Life science  Convertible Note, 6% due December 2020   70,000    76,916    0.7%
   Lifewave Biomedical Inc    Life science  Convertible Note, 6% due December 2021   50,000    51,159    0.5%
   Lowell Therapeutics Inc    Life science  Convertible Note, 8% no due date   27,491    27,955    0.3%
   mmTron Inc    Technology  Convertible Note, 4% due April 2023   100,000    101,030    0.9%
   Navaux Inc    Life science  Convertible Note, 6% due December 2023   60,000    62,841    0.6%
   Neuro42 Inc.    Life science  Convertible Note, 8% due December 2023   50,000    52,564    0.5%
   Octagon Therapeutics Inc    Life science  Convertible Note, 5% due June 2021   50,000    52,349    0.5%
   Octagon Therapeutics Inc    Life science  Convertible Note, 5% due June 2021   50,000    52,219    0.5%
   Perikinetics Inc    Life science  Convertible Note, 6% due May 2022   100,000    105,326    1.0%
   Preview Medical Inc    Life science  Convertible Note, 7% due January 2023   100,000    104,948    1.0%
   Promaxo Inc    Life science  Convertible note, 5% due July 2022   100,000    183,876    1.7%
   Rheos Inc    Life science  Convertible note, 8% due August 2026   100,000    101,074    0.9%
   Saccharo Inc    Life science  Convertible note, 7% due September 2022   50,000    50,815    0.5%
   SageMedic Corp    Life science  Convertible Note, 8% April 2021 plus warrants   50,000    59,885    0.6%
   SageMedic Corp    Life science  Convertible Note, 8% December 2022 plus warrants   75,000    79,948    0.7%
   Sensing Electromagnetic Plus Corp    Technology  Convertible Note, Fully reserved   50,000    1    0.0%
   Sensing Electromagnetic Plus Corp    Technology  Convertible Note, Fully reserved   11,048    1    0.0%
   Single Pass Inc    Life science  Convertible Note, 6% April 2024   50,000    50,970    0.5%
   Valfix Medical Inc  *   Life science  Convertible Note, 8% December 2021   50,000    54,515    0.5%
   Xpan Inc  *   Life science  Convertible Note, 8% due March 2022   50,000    56,301    0.5%
   Xpan Inc  *   Life science  Convertible Note, 8% due June 2022   25,000    27,548    0.3%
   Xpan Inc  *   Life science  Convertible Note, 8% due June 2022   25,000    27,542    0.3%
Total convertible loan investments    $3,243,539   $3,801,833    35.1%
   United States          $2,423,539   $2,873,150    

26.6

%
   Canada           470,000    537,116    5.0%
   Rest of World           350,000    391,567    3.6%
Total convertible loan investments  $3,243,539   $

3,801,833

    

35.1

%

 

Continued on next page

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

8

 

 

Continued from previous page

 

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of September 30, 2021

(Unaudited)

 

   Portfolio Company    Industry  Investment  Cost   Fair value   % of net assets (a)  
Preferred stock investments                        
   Altis Biosystems    Life science  22,028 shares of Series Seed Preferred  $50,000   $50,000   0.5 %
   Astrocyte Pharmaceuticals Inc    Life science  260,756 shares of Series A Preferred   100,000    100,000   0.9 %
   Cnote Group, Inc    Fintech  84,655 shares of series Seed-2 Preferred (converted SAFE)   51,500    59,783   0.6 %
   Cnote Group, Inc    Fintech  93,807 shares of Series Seed-3 Preferred (converted note)   50,000    66,247   0.6 %
   Colabs Inc    Life science  147,058 shares of Series A-1 Preferred   50,000    50,000   0.5 %
   Connectus Services Ltd  *   Technology  31,348 shares of Series Seed Preferred   100,000    100,000   0.9 %
   Deep Blue Medical Advances Inc    Life science  10,474 shares of Series A Preferred   49,996    49,997   0.5 %
   Eumentis Thereapeutics Inc    Life science  85,009 shares of Series A Preferred   100,000    100,000   0.9 %
   FemtoDX Inc    Life science  42,436 shares of Series A Preferred   100,000    290,046   2.7 %
   Healionics Corporation    Life science  35,075 of Series A-1 Preferred   100,000    100,000   0.9 %
   i-Lumen Scientific Inc.    Life science  50,000 shares of Series A Preferred plus warrants   50,000    50,000   0.5 %
   i-Lumen Scientific Inc.    Life science  50,000 shares of Series A Preferred plus warrants   50,000    50,000   0.5 %
   Inhalon Biopharma Inc    Life science  18,843 shares of Series Seed Preferred   99,997    99,997   0.9 %
   Light Line Medical Inc    Life science  62,849 shares of Series Seed Preferred (converted note)   30,000    38,031   0.4 %
   Light Line Medical Inc    Life science  141,871 shares of Series Seed Preferred (converted note)   70,000    106,049   1.0 %
   Light Line Medical Inc    Life science  40,323 shares of Series Seed preferred   25,000    25,000   0.2 %
   Light Line Medical Inc    Life science  72,464 shares of Series A Preferred plus warrants   50,000    50,000   0.5 %
   Lowell Therapeutics Inc    Life science  20,000 shares of Series A Preferred   50,000    50,000   0.5 %
   Lowell Therapeutics Inc    Life science  20,000 shares of Series A Preferred   50,000    50,000   0.5 %
   Lowell Therapeutics Inc    Life science  25,000 shares of Series B Preferred   100,000    100,000  

0.9

%
   Makani Science Inc    Life science  172,413 shares of Series Seed Preferred   50,000    50,000   0.5 %
   Micronic Technologies Inc    Technology  51,929 shares of Series Seed-1 Preferred plus warrants   100,000    100,000   0.9 %
   Neuroflow Inc    Life science  98,684 shares of Series Seed -2 Preferred   150,000    224,998   2.1 %
   Neuroflow Inc    Life science  20,429 shares of Series B Preferred   100,000    212,497   2.0 %
   New View Surgical, Inc.    Life science  53,825 shares of Series A-1 Preferred   75,000    75,000   0.7 %
   New View Surgical, Inc.    Life science  58,220 shares of Series A-1 Preferred   100,000    100,000   0.9 %
   Orion Biotechnology Inc  *   Life science  5,824 shares of Series A Preferred   100,000    100,000   0.9 %
   Otomagnetics Inc    Life science  16,538 shares of Series A-1 Preferred   100,000    100,000   0.9 %
   Partheous Inc    Life science  50,000 shares of Series A Preferred   50,000    50,000   0.5 %
   Promaxo    Life science  104,248 shares of Series B-1 Preferred, (converted note)   250,000    1,034,684   9.6 %
   Seal Rock Therapeutics, Inc.    Life science  68,075 shares of Series Seed Preferred, (converted note)   78,000    199,112   1.8 %
   Shyft (FKA Crater Group Inc)    Technology  42,657 shares of Series A-1 Preferred (converted note)   51,500    107,059   1.0 %
   Shyft (FKA Crater Group Inc)    Technology  28,147 shares of Series A Preferred (converted note)   50,000    91,771   0.8 %
   Shyft (FKA Crater Group Inc)    Technology  21,774 shares of Series A-1 Preferred (plus warrants)   50,000    70,990   0.7 %
( i )  Trellis Bioscience LLC    Life science  50,000 shares of Series B Preferred plus warrants   50,000    50,000   0.5 %
( i )  Trellis Bioscience LLC    Life science  50,000 shares of Series B Preferred plus warrants   50,000    50,000   0.5 %
( i )  Trellis Bioscience LLC    Life science  100,000 shares of Series B Preferred plus warrants   100,000    100,000   0.9 %
   Valfix Medical Inc  *   Life science  27,217 shares of Series Seed Preferred   50,000    50,000   0.5 %
   Vesteck Inc    Life science  34,783 shares of Series A preferred   100,000    100,000   0.9 %
   Visgenx Inc    Life science  7,833 shares of Series Seed-1 Preferred (converted note)   30,000    46,352   0.4 %
   Visgenx Inc    Life science  4,132 shares of Series Seed Preferred (converted note)   25,000    25,648   0.2 %
   Visgenx Inc    Life science  2,480 shares of Series Seed Preferred (converted note)   15,003    15,392   0.1 %
Total Preferred stock investments    $3,050,997   $4,538,653  

42.0

%
   United States          $2,800,997   $4,288,653   39.6 %
   Canada           200,000    200,000   1.8 %
   Rest of World           50,000    50,000   0.5 %
Total Preferred stock investments     $3,050,997   $4,538,653  

42.0

%
                            
Common stock investments                   
   BendaRX Corp  *   Life science  12,500 Common shares  $100,000   $150,000   1.4 %
   BendaRX Corp  *   Life science  12,500 Common shares   100,000    150,000   1.4 %
   Boardwalk Tech    Technology  75,000 Common shares   65,600    65,600   0.6 %
   Boardwalk Tech    Technology  150,000 Common shares   73,500    91,995   0.9 %
   Kuantsol Inc    Technology  133.333 Common shares   25,000    25,000   0.2 %
   Sanaby Health Sponsor LLC    Life science  50,000 Common shares   100,000    473,732   4.4 %
Total Common stock investments      $464,100   $956,327   4.2 %
   United States          $264,100   $656,327   6.1 %
   Canada  

 

         200,000    300,000   2.8 %
   Rest of World  

 

         -    -  
Total Common stock investments    $464,100   $956,327   8.8 %
      *                      
SAFE investments                   
   Infinidome Ltd  *   Technology  SAFE  $50,000   $50,000   0.5 %
   Infinidome Ltd  *   Technology  SAFE   50,000    50,000   0.5 %
   Madorra Inc  *   Life science  SAFE   100,000    100,000   0.9 %
   Mitre Medical Corp    Life science  SAFE   75,000    75,000   0.7 %
   Mitre Medical Corp    Life science  SAFE   50,000    50,000   0.5 %
   Orion Biotechnology Inc.  *   Life science  SAFE   100,000    100,000   0.9 %
   Polymertal Ltd  *   Technology  SAFE   150,000    150,000   1.4 %
Total SAFE investments    $575,000   $575,000   5.3 %
   United States           125,000    125,000   1.2 %
   Canada           100,000    100,000   0.9 %
   Rest of World           350,000    350,000   3.2 %
Total SAFE investments     $575,000   $575,000   5.3 %

 

Continued on next page

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

9

 

 

Continued from previous page

 

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of September 30, 2021

(Unaudited)

 

   Portfolio Company  Industry  Investment  Cost   Fair value   % of net assets (a) 
Other investments                     
   Enduralock LLC  Technology  34.1 Series A-1 Ownership Units  $30,000   $30,000    0.3%
   Enduralock LLC  Technology  39.7 Series A-1 Ownership Units   35,000    35,000    0.3%
( i )  Exodos Life Sciences LP  Life science  Class A-1 Preferred Ownership Units   206,000    206,000    1.9%
   Green Sun Medical LLC  Life science  2,193 Class A-1 Ownership units   50,000    50,000    0.5%
   Green Sun Medical LLC  Life science  1,096 Class A-1 Ownership units   25,000    25,000    0.2%
   Green Sun Medical LLC  Life science  1,096 Class A-1 Ownership units   25,000    25,000    0.2%
   Green Sun Medical LLC  Life science  4,386 Class A-1 Ownership units   100,000    100,000    0.9%
   Riso Capital Fund I, LP  Technology  Ownership units   50,000    50,000    0.5%
   Riso Capital Fund I, LP  Technology  Ownership units   50,000    50,000    0.5%
Total other investments        $571,000   $571,000    5.3%
   United States        $571,000   $571,000    5.3%
   Canada         -    -    
   Rest of World         -    -    
Total other investments        $571,000   $571,000    5.3%
                         
Total investments        $7,904,636   $10,442,813    96.5%
   United States        $6,184,636   $8,514,130    78.7%
   Canada         970,000    1,137,116    10.5%
   Rest of World         750,000    791,567    7.3%
Total investments        $7,904,636   $10,442,813    96.5%
   (a) based on total net assets of$ 10,817,894                  

  

( i ) Kyto representatives sit on the Board of Directors of these companies.

* These companies  are headquartered outside of the US.

 

  The accompanying notes are an integral part of these condensed interim financial statements.

 

10

 

 

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of March 31, 2021

(Unaudited)

 

      Portfolio Company         Industry   Investment     Cost     Fair value     % of net assets (a)  
Convertible loan investments                                          
(i)     Achelios Therapeutics Inc.           Life science     Convertible Note, 8% due, December 2021     $ 100,000     $ 121,173     1.7 %
(i)     Achelios Therapeutics Inc.           Life science     Convertible Note, 8% due December 2021       25,000       29,033     0.4 %
(i)     Achelios Therapeutics Inc.           Life science     Convertible Note, 8% due December 2021       50,000       54,581     0.8 %
      Avisi Technologies Inc           Life science     Convertible Note, 8% due July 2022       50,000       52,674     0.8 %
      Basepaws Inc           Life science     Convertible Note, 1% due April 2020       50,000       162,319     2.3 %
(i)     Beam Semiconductor Inc     *     Technology     Convertible Note, 8% due April 2022       150,000       171,041     2.4 %
(i)     Beam Semiconductor Inc     *     Technology     Convertible Note, 8% due March 2021       50,000       54,285     0.8 %
      Corinnova Inc           Life science     Convertible Note, 6% due December 2024       100,000       102,318     1.5 %
      Cyberdontics Inc     *     Life science     Convertible Note, 8% due September 2022       30,000       33,768     0.5 %
      Cyberdontics Inc     *     Life science     Convertible Note, 8% due February 2023       35,000       38,053     0.5 %
      Cyberdontics Inc     *     Life science     Convertible Note, 0% no due date       35,000       36,296     0.5 %
      Deep Blue Medical Advances Inc           Life science     Convertible Note, 6% due June 2022       50,000       50,863     0.7 %
      Every Key Inc           Technology     Convertible Note, 5% due December 2023       100,000       106,521     1.5 %
      Identical Inc           Life science     Convertible Note, 2% due May 2022       100,000       100,844     1.4 %
      INBay Technology Inc     *     Technology     Convertible Note, 12% due October 2020       50,000       59,721     0.9 %
      INBay Technology Inc     *     Technology     Convertible Note, 12% due July 2021       30,000       34,149     0.5 %
      INBay Technology Inc     *     Technology     Convertible Note, 12% due February 2022       50,000       56,641     0.8 %
      INBay Technology Inc     *     Technology     Convertible Note, 12% due December 2022       40,000       41,552     0.6 %
      Kiana Analytics Inc           Technology     Convertible Note, 3% December 2022       100,000       100,847     1.4 %
      Kitotech Medical Inc           Life science     Convertible Note, 6% due December 2020       100,000       243,133     3.5 %
      Kitotech Medical Inc           Life science     Convertible Note, 6% due November 2022       75,000       83,738     1.2 %
      Lifewave Biomedical Inc           Life science     Convertible Note, 6% due December 2020       30,000       32,831     0.5 %
      Lifewave Biomedical Inc           Life science     Convertible Note, 6% due December 2020       70,000       74,810     1.1 %
      Navaux Inc           Life science     Convertible Note, 6% due December 2023       60,000       61,036     0.9 %
      Neuro42 Inc.           Life science     Convertible Note, 8% due December 2023       50,000       50,559     0.7 %
      Octagon Therapeutics Inc           Life science     Convertible Note, 5% due June 2021       50,000       51,110     0.7 %
      Octagon Therapeutics Inc           Life science     Convertible Note, 5% due June 2021       50,000       50,966     0.7 %
      Perikinetics Inc           Life science     Convertible Note, 6% due May 2022       100,000       102,318     1.5 %
      Preview Medical Inc           Life science     Convertible Note, 7% due January 2023       100,000       101,918     1.5 %
      SageMedic Corp           Life science     Convertible Note, 8% April 2021 plus warrants       50,000       57,879     0.8 %
      SageMedic Corp           Life science     Convertible Note, 8% December 2022 plus warrants       75,000       77,088     1.1 %
      Sensing Electromagnetic Plus Corp           Technology     Convertible Note, Fully reserved       50,000       1     0.0 %
      Sensing Electromagnetic Plus Corp           Technology     Convertible Note, Fully reserved       11,048       1     0.0 %
      Valfix Medical Inc     *     Life science     Convertible Note, 8% December 2021       50,000       52,510     0.8 %
      Xpan Inc     *     Life science     Convertible Note, 8% due March 2022       50,000       54,296     0.8 %
      Xpan Inc     *     Life science     Convertible Note, 8% due June 2022       25,000       26,545     0.4 %
      Xpan Inc     *     Life science     Convertible Note, 8% due June 2022       25,000       26,540     0.4 %
Total Convertible loan investments                   $ 2,216,048     $ 2,553,954     36.5 %
      United States                       $ 1,596,048     $ 1,868,557     26.7 %
      Canada                         370,000       407,561     5.8 %
      Rest of World                         250,000       277,836     4.0 %
Total Convertible loan investments                   $ 2,216,048     $ 2,553,954     36.5 %

 

Continued on next page

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

11

 

 

Continued from previous page

 

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of March 31, 2021 - continued

(Unaudited)

 

Preferred stock investments                    
   Altis Biosystems    Life science  22,028 shares of Series Seed Preferred  $50,000   $50,000   0.7 %
   Astrocyte Pharmaceuticals Inc    Life science  260,756 shares of Series A Preferred   100,000    100,000   1.4 %
   Cnote Group, Inc    Fintech  84,655 shares of series Seed-2 Preferred (converted SAFE)   51,500    59,783   0.9 %
   Cnote Group, Inc    Fintech  93,807 shares of Series Seed-3 Preferred (converted note)   50,000    66,247   0.9 %
   Colabs Inc    Life science  147,058 shares of Series A-1 Preferred   50,000    50,000   0.7 %
   Connectus Services Ltd *  Technology  31,348 shares of Series Seed Preferred   100,000    100,000   1.4 %
   Deep Blue Medical Advances Inc    Life science  10,474 shares of Series A Preferred   49,997    49,997   0.7 %
   Eumentis Thereapeutics Inc    Life science  85,009 shares of Series A Preferred   100,000    100,000   1.4 %
   FemtoDX Inc    Life science  42,436 shares of Series A Preferred   100,000    159,835   2.3 %
   i-Lumen Scientific Inc.    Life science  50,000 shares of Series A Preferred plus warrants   50,000    50,000   0.7 %
   i-Lumen Scientific Inc.    Life science  50,000 shares of Series A Preferred plus warrants   50,000    50,000   0.7 %
   Inhalon Biopharma Inc    Life science  18,843 shares of Series Seed Preferred   99,997    99,997   1.4 %
   Light Line Medical Inc    Life science  62,849 shares of Series Seed Preferred (converted note)   30,000    38,031   0.5 %
   Light Line Medical Inc    Life science  141,871 shares of Series Seed Preferred (converted note)   70,000    106,049   1.5 %
   Light Line Medical Inc    Life science  40,323 shares of Series Seed preferred   25,000    25,000   0.4 %
   Light Line Medical Inc    Life science  72,464 shares of Series A Preferred plus warants   50,000    50,000   0.7 %
   Lowell Therapeutics Inc    Life science  20,000 shares of Series A Preferred   50,000    50,000   0.7 %
   Lowell Therapeutics Inc    Life science  20,000 shares of Series A Preferred   50,000    50,000   0.7 %
   Micronic Technologies Inc    Technology  51,929 shares of Series Seed-1 Preferred plus warrants   100,000    100,000   1.4 %
   Neuroflow Inc    Life science  98,684 shares of Series Seed -2 Preferred   150,000    224,998   3.2 %
   Neuroflow Inc    Life science  20,429 shares of Series B Preferred   100,000    212,497   3.0 %
   New View Surgical, Inc.    Life science  53,825 shares of Series A-1 Preferred   75,000    75,000   1.1 %
   Otomagnetics Inc    Life science  16,538 shares of Series A-1 Preferred plus warrants   100,000    100,000   1.4 %
   Promaxo    Life science  104,248 shares of Series B-1 Preferred, (converted note)   250,000    531,738   7.6 %
   Seal Rock Therapeutics, Inc.    Life science  68,075 shares of Series Seed Preferred, (converted note)   78,000    80,329   1.1 %
   Shyft (FKA Crater Group Inc)    Technology  42,657 shares of Series A-1 Preferred   51,500    97,940   1.4 %
   Shyft (FKA Crater Group Inc)    Technology  28,147 shares of Series A Preferred (converted note)   50,000    64,626   0.9 %
   Shyft (FKA Crater Group Inc)    Technology  21,774 shares of Series A-1 Preferred (converted note)   50,000    50,000   0.7 %
(i)  Trellis Bioscience LLC    Life science  50,000 shares of Series B Preferred plus warrants   50,000    50,000   0.7 %
(i)  Trellis Bioscience LLC    Life science  50,000 shares of Series B Preferred plus warrants   50,000    50,000   0.7 %
(i)  Trellis Bioscience LLC    Life science  100,000 shares of Series B Preferred plus warrants   100,000    100,000   1.4 %
   Valfix Medical Inc *  Life science  27,217 shares of Series Seed Preferred   50,000    50,000   0.7 %
   Visgenx Inc    Life science  7,833 shares of Series Seed-1 Preferred (converted note)   30,000    46,352   0.7 %
   Visgenx Inc    Life science  4,132 shares of Series Seed Preferred (converted note)   25,000    25,648   0.4 %
   Visgenx Inc    Life science  2,480 shares of Series Seed Preferred (converted note)   15,003    15,392   0.2 %
Total Preferred stock investments

  
        $2,450,998   $3,129,458   44.8 %
   United States           $2,300,998   $2,979,458   42.6 %
   Canada            100,000    100,000   1.4 %
   Rest of World            50,000    50,000   0.7 %
Total Preferred stock investments           $2,450,998   $3,129,458   44.8 %
                             
Common stock investments                         
   BendaRX Corp *  Life science  12,500 Common shares  $100,000   $150,000   2.1 %
   BendaRX Corp *  Life science  12,500 Common shares   100,000    150,000   2.1 %
   Boardwalk Tech    Technology  150,000 Common shares   73,500    91,995   1.3 %
Total common stock investments          $273,500   $391,995   5.6 %
   United States          $73,500   $91,995   1.3 %
   Canada           200,000    300,000   4.3 %
   Rest of World           -    -  
Total common stock investments          $273,500   $391,995   5.6 %
                            
SAFE investments                        
   Infinidome Ltd *  Technology  SAFE  $50,000   $50,000   0.7 %
   Infinidome Ltd *  Technology  SAFE   50,000    50,000   0.7 %
   Mitre Medical Corp    Life science  SAFE   75,000    75,000   1.1 %
   Mitre Medical Corp    Life science  SAFE   50,000    50,000   0.7 %
   Orion Biotechnology Inc. *  Life science  SAFE   100,000    100,000   1.4 %
Total SAFE investments          $325,000   $325,000   4.6 %
   United States           $125,000   $125,000   1.8 %
   Canada           100,000    100,000   1.4 %
   Rest of World           100,000    100,000   1.4 %
Total SAFE investments          $325,000   $325,000   4.6 %

 

Continued on next page

 

The accompanying notes are an integral part of these condensed interim financial statements.

 

12

 

 

Continued from previous page

 

Kyto Technology and Life Science, Inc.

Condensed Schedule of Investments as of March 31, 2021 - continued

(Unaudited)

 

Preferred stock investments                        
Other investments                        
   Enduralock LLC    Technology  34.1 Series A-1 Ownership Units  $30,000   $30,000   0.4 %
   Enduralock LLC    Technology  39.7 Series A-1 Ownership Units   35,000    35,000   0.5 %
(i)  Exodos Life Sciences LP    Life science  Class A-1 Preferred Ownership Units   206,000    206,000   2.9 %
   Green Sun Medical LLC    Life science  2,193 Class A-1 Ownership units   50,000    50,000   0.7 %
   Green Sun Medical LLC    Life science  1,096 Class A-1 Ownership units   25,000    25,000   0.4 %
   Green Sun Medical LLC    Life science  1,096 Class A-1 Ownership units   25,000    25,000   0.4 %
   Riso Capital Fund I, LP    Technology  Ownership units   50,000    50,000   0.7 %
Total other investments          $421,000   $421,000   6.0 %
   United States          $421,000   $421,000   6.0 %
   Canada           -    -  
   Rest of World           -    -  
Total Other investments          $421,000   $421,000   6.0 %
                            
Total investments          $5,686,545   $6,821,407   97.5 %
   United States          $4,516,546   $5,486,011   78.4 %
   Canada           770,000    907,560   13.0 %
   Rest of World           400,000    427,836   6.1 %
Total investments          $5,686,545   $6,821,407   97.5 %
                            
   (a) based on total net assets of  $ 6,993,163                                                     

 

( i ) Kyto representatives sit on the Board of Directors of these companies.
* These companies are headquartered outside of the US.
  The accompanying notes are an integral part of these condensed interim financial statements.

 

13

 

 

KYTO TECHNOLOGY AND LIFE SCIENCE INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2021

 

NOTE 1 – DESCRIPTION OF BUSINESS

 

Kyto Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.

 

The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early-stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early-stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.

 

The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, Mr. Russo was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% was paid monthly from January to April 2021, then 75% from May 2021, with the balance being deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in a Form 8-K filed on February 1, 2021, which was approved by the Compensation committee of the Board of Directors on that date. During the three months and six months ended September 30, 2021, Mr. Russo received gross pay of $90,000 and $170,000, respectively. No consulting fees and no options were granted to him during these periods. During the three months and six months ended September 30, 2020, Mr. Russo received no payroll or consulting fees, however in the three and six months ended September 30, 2020 he received a bonus of $50,000 and was granted options to purchase 215,000 shares of Common stock.

 

The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

 

14

 

 

At March 31, 2020, management determined that the Company was an investment company for purposes of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946) disclosure, and adopted the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).

 

As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.

 

NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

(A) BASIS OF PRESENTATION

 

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which the Company considers necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three months and six months ended September 30, 2021 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The condensed balance sheet as of March 31, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by U.S. GAAP. The information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements of the Company for the year ended March 31, 2021, included in the Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2021.

 

The Company’s condensed interim financial statements are prepared in accordance with U.S. GAAP, which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition, income tax uncertainties, stock-based compensation, and other contingencies.

 

The Company’s financial statements are prepared using the specialized accounting principles of ASC Topic 946. In accordance with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments. The carrying amount of the Company’s financial instruments such as cash and payables approximates fair value due to the short maturity of such instruments. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.

 

15

 

 

(B) INVESTMENT TRANSACTIONS AND NET REALIZED AND UNREALIZED GAIN OR LOSS ON INVESTMENTS

 

The Company generates increases or decreases in its net assets from the sale of complete or partial investments following a merger or acquisition (“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in their fair value, either upwards or downwards. As a minority early-stage investor, the Company does not have the ability to manage the timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a general guideline, it would expect such events to occur approximately four to five years after its investments are made. The Company records the realized gains and losses from investment activities upon completion of sale and receipt of net proceeds, after deducting related transaction expenses. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized. The Company is in periodic contact with the management of its portfolio investment companies to provide a basis for valuation changes. The Company does not expect to receive interest and principal repayments on its convertible notes and generally expects these notes to convert into equity securities upon completion of qualified subsequent financings. Accrued interest is recorded as an adjustment to the fair value of the convertible notes.

 

(C) INCOME TAXES

 

The Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 “Accounting for Income Taxes” (“Topic 740”). Under Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date.

 

(D) USE OF ESTIMATES

 

In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.

 

Significant estimates during the three months and six months ended September 30, 2021 and September 30, 2020 include the valuation of the investment portfolio, deferred tax assets, tax valuation allowance, stock options and warrants.

 

(E) CASH AND CASH EQUIVALENTS

 

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at September 30, 2021 and March 31, 2021, respectively.

 

(F) CONCENTRATIONS

 

The Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of September 30, 2021, and March 31, 2021, the Company’s bank balance exceeded the federally insured limit by approximately $70,000 and $1.2 million, respectively. The Company has not experienced any losses in such accounts through September 30, 2021.

 

16

 

 

(G) STOCK-BASED COMPENSATION

 

Financial Accounting Standards Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that all equity awards granted to employees and consultants be accounted for at fair value. This fair value is measured at grant date for stock settled awards, and at subsequent exercise or settlement for cash-settled awards. Under this method, the Company records an expense equal to the fair value of the options or warrants issued. The fair value is computed using the Black Scholes options pricing model. The Company granted consultants and advisors 490,000 and 510,000 options during the three months ended September 30, 2021 and September 30, 2020, and 740,000 and 510,000 options during the six months ended September 30, 2021 and September 30, 2020, respectively.

 

(H) NET EARNINGS PER COMMON SHARE

 

In accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, “Earnings per Share”, basic earnings per common share is computed by dividing the net income less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings per common share is computed by dividing net income less preferred dividends by the weighted average number of common shares outstanding including the effect of common stock equivalents consisting of preferred stock, stock options and warrants. The following table sets out the number of shares used in calculating fully- diluted earnings per common share using the if-converted method.

 

Weighted Average method

 

Number of shares used in calculating fully- diluted earnings per common shares

 

  

Three months
ended
September 30,
2021

  

Six months
ended
September 30,
2021

 
Common Stock   13,271,996    13,269,764 
Common stock subscribed not issued   -    - 
Series A preferred stock   4,200,000    4,200,000 
Series B preferred stock   5,307,240    4,361,525 
Options   2,962,792    2,835,262 
Warrants   1,596,667    1,596,667 
           
Total shares used in calculating fully-diluted earnings per common share   27,338,695    26,263,218 

 

   Three months
ended
September 30,
2020
  

Six months
ended
September 30,
2020

 
Common Stock issued   5,836,832    5,836,832 
Series A preferred stock   4,200,000    4,200,000 
Series B preferred stock   1,830,208    1,250,595 
Options   1,920,000    1,571,429 
Warrants   4,200,000    4,200,000 
           
Total shares used in calculating fully-diluted earnings per common share   17,987,040    17,058,856 

 

17

 

 

(I ) INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE

 

The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their fair values. In the event that management considers the fair value of an investment to be greater or less than the current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.

 

The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing U.S. GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.

 

The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.

 

For investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.

 

In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.

 

The estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.

 

The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy are defined as follows:

 

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data

 

Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. Most of the Company’s investments are Level 3.

 

18

 

 

Critical accounting policies and practices are the policies that are both most important to the portrayal of the Company’s financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain. These include estimates of the fair value of Level 3 investments and other estimates that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. The Company’s estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 – Significant Accounting Policies” to our financial statements as of March 31, 2021, as filed with the SEC on August 10, 2021, for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.

 

(J) RECENT ACCOUNTING PRONOUNCEMENTS

 

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

 

(K) OTHER CURRENT ASSETS

 

Other current assets principally include deferred offering costs. Since April 2019, the Company has conducted a series of sales of common and preferred stock to fund its ongoing investment program and cost of operations. Typically, it expects that raising capital through the sale of any series of securities, from start to finish, may take from six to nine months and in order to match the cost and benefits of this process, the Company adopted a policy of capitalizing direct expenses incurred in the course of raising capital, with the intention of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At September 30, 2021 and March 31, 2021, the Company had deferred $230,434 and $169,891, respectively, of such expenses, relating to the preparation and filing of an N-2 Registration Statement.

 

NOTE 3 – COMMITMENTS AND CONTINGENCIES

 

The Company has no commitments or contingencies as of the date of this filing. The Company may be subject to litigation during the normal course of business but has not received any such claims to date.

 

NOTE 4 - RELATED PARTY TRANSACTIONS

 

At September 30, 2021 and March 31, 2021, the Company had accrued and owed $87,000 and $51,420, respectively, to officers of the Company for deferred payroll and consulting service fees.

 

At September 30, 2021, officers or directors of the Company held board positions at four portfolio companies: Beam Semiconductor Inc., Trellis Bioscience Inc., Exodos Life Sciences LP, and Achelios Therapeutics Inc.

 

19

 

 

NOTE 5 – INVESTMENTS

 

The following table summarizes the Company’s investment portfolio at September 30, 2021 and March 31, 2021.

 

   September 30, 2021       March 31, 2021     
Number of portfolio companies   66         51      
Fair value  $10,442,813        $6,821,407      
Cost   7,904,636         5,686,545      
                     
% of portfolio at fair value                    
Convertible notes   3,801,833    36.4%   2,553,954    37.4%
Preferrred stock   4,538,653    43.5%   3,129,458    45.9%
Common stock   956,327    9.2%   391,995    5.7%
SAFE   575,000    5.5%   325,000    4.8%
Other ownership units   571,000    5.5%   421,000    6.2%
Total  $10,442,813    100%  $6,821,407    100%

 

A SAFE is a Simple Agreement for Future Equity in the form of a warrant to purchase equity stock in a future priced round.

 

Our investment portfolio represents approximately 96% of our net assets at September 30, 2021 and 98% at March 31, 2021. Investments in early-stage start-up private operating entities are valued based on available metrics, such as relevant market multiples and comparable company valuations, company specific-financial data including subsequent financings, actual and projected results, and independent third-party valuation estimates.

 

Significant Unobservable Inputs for Level 3 Assets and Liabilities

 

In accordance with FASB ASC 820, Fair Value Management, the tables below provide quantitative information about the Company’s fair value measurements of its Level 3 assets as of September 30, 2021 and March 31, 2021. In addition to the techniques and inputs noted in the tables above, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not meant to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. To the extent an unobservable input is not reflected in the tables below, such input is deemed insignificant with respect to the Company’s Level 3 fair value measurements. Significant changes in the inputs in isolation would result in a significant change in the fair value measurement, depending on the materiality of the investment.

 

20

 

 

The following table summarizes the valuation techniques and significant unobservable inputs used for investments that are categorized within Level 3 of the fair value hierarchy as of September 30, 2021 and March 31, 2021:

 

   As of September 30, 2021 
   Fair Value   Valuation Approach/ Technique  Unobservable Inputs  Range/ Weighted Average
              
Convertible notes: Basepaws Inc  $201,663   Market approach based on indicative term sheet and last round of financing  As if converted note and Series A term sheet of $37.5 million  50:50 weight
Convertible notes: Promaxo Inc   183,876   Market approach based on available comparables and financial performance  Conversion prospects, market yield, remaining maturity   5% yield
Convertible notes: Other   3,416,294   Market approach based on available comparables and financial performance  Conversion prospects, market yield, remaining maturity   1-12% yield
Preferred stock in private companies” Shyft Moving Inc   269,820   Market approach based on indicative term sheet and last round of financing  50/50 weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from investor deck and 75% percentile for public company peer valuation ratios  Based on Series B valuation of $80 million
Preferred stock in private companies: Seal Rock Therapeutics Inc   199,112   Market approach based on indicative term sheet and last round of financing  50/50 weighting to prior Series seed preferred and indicated Note price. 75% percentile for public company peer valuation ratios  Based on new Note indication of $80 million
Preferred stock in private companies: Femto DX Inc   290,046   Market approach based on indicative term sheet and last round of financing  50/50 weighting to prior Series B-2 preferred price and public market. 75% percentile for public company peer valuation ratios  Based on Series B valuation of $170 million
Preferred stock in private companies: Promaxo Inc   1,034,984   Market approach based on available comparables and financial performance 

a) Last round of financing for series B-2 price, 118% change in enterprise value @75th percentile b) revenue multiples 2021 13.3X 2022 9.3x

  0%-168.3% 0.6x - 27.7x 0.5x - 59.4x
Preferred stock in private companies: Other   2,744,691   Market approach based on available comparables and financial performance  Market approach based on available information from portfolio companies  Various
Common stock in private companies   325,000   Market approach based on available comparables and financial performance  Historic or projected revenue and/or EBITDA multiples discounted for lack of marketability  Various
SAFE   575,000   Market approach based on available comparables and financial performance  Precedent and follow-on transactions adjusted for marketability  Various
Other investments   571,000   Market approach based on available comparables and financial performance  Precedent and follow-on transactions adjusted for marketability  Various
Total Investments  $9,811,486          

 

   As of March 31, 2021 
   Fair Value   Valuation Approach/ Technique  Unobservable Inputs  Range/ Weighted Average
              
Convertible notes: Kitotech Medical Inc  $326,871   Market approach based on available comparables and financial performance  Market cap of $28.51 million a, Public company 75th percentile As if converted 2020 note  Range : $28.514 million
Convertible notes  2,227,083   Market approach based on available comparables and financial performance  Conversion prospects, market yield, remaining maturity   1-12% yield
Preferred stock in private companies: Femto DX Inc   159,835   Market approach based on available comparables and financial performance  Based on Series B financing and public company peer multiples using 50:50 percentile  Market value of invested capital $58.66 million
Preferred stock in private companies: Neuroflow Inc   437,495   Market approach based on available comparables and financial performance  Based on Series Seed 2 and last round of financing - Series B  Market value of invested capital $57.98 million
Preferred stock in private companies: other   2,532,128   Market approach based on available comparables and financial performance  Market approach based on available information from portfolio companies  Various
Common stock in private companies   300,000   Market approach based on available comparables and financial performance  Historic or projected revenue and/or EBITDA multiples  Various
SAFE   325,000   Market approach based on available comparables and financial performance  Precedent and follow-on transactions adjusted for marketability  Various
Other investments   421,000   Market approach based on available comparables and financial performance  Precedent and follow-on transactions adjusted for marketability  Various
Total Investments  $6,729,412          

 

21

 

 

The following table presents fair value measurements of investments, by major class, as of September 30, 2021, and March 31, 2021, according to the fair value hierarchy:

 

   As of September 30, 2021 
   Quoted prices in active markets for identical securities   Significant other observable inputs   Significant unobservable inputs     
Description  (Level 1)   (Level 2)   (Level 3)   Total 
Investments at Fair Value                    
Private Portfolio Companies                    
Convertible notes  $-   $  -   $3,801,833   $3,801,833 
Preferred stock   -    -    4,538,653    4,538,653 
Common stock   -    -    325,000    325,000 
SAFEs   -    -    575,000    575,000 
Other ownership interests   -    -    571,000    571,000 
    -    -    9,811,486    9,811,486 
Public Portfolio Companies                    
Common stock   631,327    -    -    631,327 
                     
Total Investments at Fair value  $631,327   $-   $9,811,486   $10,442,813 

 

   As of March 31, 2021 
Description  Level 1   Level 2   Level 3   Total 
March 31, 2021                
Investments at Fair Value                    
Private Portfolio Companies                    
Convertible notes  $-   $-   $2,553,954   $2,553,954 
Preferred stock   -    -    3,129,458    3,129,458 
Common stock   -    -    300,000    300,000 
SAFEs   -    -    325,000    325,000 
Other ownership interests   -    -    421,000    421,000 
    -    -    6,729,412    6,729,412 
                     
Public Portfolio Companies                    
Common stock   91,995    -    -    91,995 
                     
Total Investments at Fair value  $91,995   $-   $6,729,412   $6,821,407 

 

As of September 30, 2021, and March 31, 2021, all our investments were treated as Level 3 with the exception of two which are invested in common stock of a public company and treated as Level 1.

 

We focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in U.S. dollars. Assets that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes in market prices of such securities. Such foreign currency translation gains and losses are included in the net realized gains or losses from investments and net changes in unrealized gain or losses from investments on the statement of operations.

 

22

 

 

   America   Canada   Rest of World   Total 
Fair value beginning of year March 31, 2021  $5,486,011   $907,560   $427,836   $6,821,407 
New investments   1,668,091    200,000    350,000    2,218,091 
Proceeds from sale of investments   -    -    -    - 
Realized gains   -    -    -    - 
Net change in unrealized gains included in condensed Statements of Operations   1,360,028    29,556    13,731    1,403,315 
Fair value end of six months September 30, 2021  $8,514,130   $1,137,116   $791,567   $10,442,813 
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.                 $1,403,315 

 

   America   Canada   Rest of World   Total 
Fair value beginning of year March 31, 2020  $2,170,499   $245,000   $250,000   $2,665,499 
New investments   540,000    150,000    50,000    740,000 
Proceeds from sale of investments   -    -    -    - 
Realized gains   -    -    -    - 
Net change in unrealized gains included in condensed Statements of Operations   438,953    21,947    17,348    478,248 
Fair value end of six months September 30, 2020  $3,149,452   $416,947   $317,348   $3,883,747 
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.                 $478,248 

 

Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.

 

   Fintech   Technology   Life science   Total 
Fair value beginning of year March 31, 2021  $126,030   $1,394,318   $5,301,059   $6,821,407 
New investments   -    590,600    1,627,491    2,218,091 
Proceeds from sale of investments   -    -    -    - 
Realized gains   -    -    -    - 
Net change in unrealized gains included in condensed Statements of Operations   -    45,531    1,357,784    1,403,315 
Fair value end of six months September 30, 2021  $126,030   $2,030,449   $8,286,334   $10,442,813 
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.                 $1,403,315 

 

   Fintech   Technology   Life science   Total 
Fair value beginning of year March 31, 2020  $101,500   $685,002   $1,878,997   $2,665,499 
New investments   -    -    740,000    740,000 
Proceeds from sale of investments   -    -    -    - 
Realized gains   -    -    -    - 
Net change in unrealized gains included in condensed Statements of Operations   24,530    37,769    415,949    478,248 
Fair value end of six months September 30, 2020  $126,030   $722,771   $3,034,946   $3,883,747 
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.                 $478,248 

 

23

 

 

We invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically, we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired, we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible note investment exceeds its maturity date we would request the portfolio company to document an extension, as well as consider whether the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be an adjustment in fair value of the investment. There were no transfers into or out of Level 3 during the three and six months ended September 30, 2021 and September 30, 2020.

 

   Convertible notes   Preferred stock   Common stock   SAFEs   Other ownership interests   Total 
                         
Fair value March 31, 2021  $2,553,954   $3,129,458   $391,995   $325,000   $421,000   $6,821,407 
Conversions into preferred stock   -    -    -    -    -    - 
New investments   1,027,491    600,000    190,600    250,000    150,000    2,218,091 
Proceeds from sale of investments   -    -    -    -    -    - 
Realized gains   -    -    -    -    -    - 
Unrealized gains included in condensed Statements of Operations   220,388    809,195    373,732    -    -    1,403,315 
Fair value September 30, 2021  $3,801,833   $4,538,653   $956,327   $575,000   $571,000   $10,442,813 

 

   Convertible notes   Preferred stock   Common stock   SAFEs   Other ownership interests   Total 
                         
Fair value March 31, 2020  $1,528,002   $701,497   $126,500   $73,500   $236,000   $2,665,499 
Conversions into preferred stock   (597,984)   678,313    -    (80,329)   -    - 
New investments   100,000    440,000    100,000    -    100,000    740,000 
Proceeds from sale of investments   -    -    -    -    -    - 
Realized gains   -    -    -    -    -    - 
Unrealized gains included in condensed Statements of Operations   178,986    279,433    (62,000)   81,829    -    478,248 
Fair value September 30, 2020  $1,209,004   $2,099,243   $164,500   $75,000   $336,000   $3,883,747 

 

NOTE 6– EQUITY

 

(A) PREFERRED STOCK

 

Series A

 

The Company has sold 4,200,000 Series A Stock Units (“Units”) consisting of one share of Series A Preferred Stock and one warrant to purchase a share of Common Stock at $0.80 per share. The Units were sold in a private placement to accredited investors. The Series A Preferred Stock will be converted into shares of Common Stock upon listing of the Company on Nasdaq or NYSE. In the event of any liquidation or winding up of the Company, the holders of the Series A shall be entitled to receive in preference to the holders of shares of Common Stock a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). All share issuances and obligations are recognized on the books and stock register.

 

On March 2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series A-1 and Series A-2 Preferred Stock were created, and the holders of Series A Preferred Stock were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of Common Stock, their shares of Series A Preferred Stock were exchanged for Series A-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of Common Stock their Series A Preferred Stock were exchanged for Series A-2 Preferred Stock which in turn is convertible into shares of Common Stock at a discount of 10% to the IPO price. In all other respects the Series A-1 and Series A-2 Preferred Stock has the same rights and obligations as the Series A Preferred Stock. As of September 30, 2021, 1,437,500 shares of Series A Preferred Stock had been exchanged for Series A-1 Preferred Stock, and 2,212,500 shares of Series A Preferred Stock had been exchanged for Series A-2 Preferred Stock, respectively, leaving outstanding 550,000 shares of Series A Preferred Stock (“Series A”) designated at a par value of $0.01 per share.

 

24

 

 

Series B

 

There were also 6,000,000 shares of Series B Preferred Stock (“Series B”) authorized designated at a par value of $0.01 per share. The Series B can be converted into shares of Common Stock upon listing of the Company on Nasdaq. In the event of any liquidation or winding up of the Company, the holders of the Series B shall be entitled to receive in preference to the holders of Common Shares and Series A Preferred Stock, a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). The holders of Series B shall be entitled to receive out of any funds of the Corporation at a time legally available for the declaration of dividends, dividends at a cumulative rate of 10% under such terms and conditions as the Board shall prescribe, provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Series B shall be payable before any dividends shall be declared or paid upon or set apart for the Common Stock.

 

On March 2, 2021, in preparation for an intended future IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series B-1 and Series B-2 Preferred Stock (“Series B-1” and “Series B-2”, respectively) were created, and the holders of the Series B were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of Common Stock, their Series B were exchanged for Series B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of Common Stock their Series B were exchanged for Series B-2 which converts into shares of Common Stock at a discount of 10% to the IPO price. In all other respects, the Series B-1 and Series B-2 have the same rights and obligations as the Series B. At September 30, 2021, 1,166,406 shares of Series B had been exchanged for Series B-1, and 2,176,250 shares of Series B had been exchanged for Series B-2, respectively, leaving outstanding 286,250 shares of Series B. During the three and six months ended September 30, 2021, the Company sold 1,591,250 and 2,282,500 shares of Series B-1 Preferred Stock for $1,273,000 and $1,826,001, respectively.

 

As of September 30, 2021, the Company authorized an additional 3,000,000 shares of Series B stock designated as Series B-3 Preferred (“Series B-3”) bringing Series B to a total of 9,000,000 authorized shares with a par value of $0.01 per share. The Certificate of Designation of the Series B-3 shares was filed with the Delaware Secretary of State on October 5, 2021. The Series B-3 will be offered for $0.80 per share and accrue a cumulative dividend of 10% per annum. The remaining terms and conditions are substantially the same as for all other Series B shares, including mandatory conversion upon a majority vote of the Series B-3 shareholders, closing of a qualified financing of at least $10 million, or listing on a public stock exchange.

 

B) COMMON STOCK

 

The Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of September 30, 2021, and March 31, 2021 a total of 13,287,621 and 9,983,082 shares of the Company’s common stock were issued and outstanding, respectively.

 

During the three and six months ended September 30, 2021, in connection with the amendment of Preferred Stock rights described in A above, the Company sold 3,285,789 shares of Common Stock for $1,314,317 of which $1,191,442 was received and accrued as subscription liability at March 31, 2021.

 

During each of the three and six months ended September 30, 2021, the Company issued 18,750 shares of Common Stock for $618, respectively, in connection with the exercise of stock options.

 

25

 

 

C) STOCK OPTIONS

 

In April 2018, the Board approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan (“the 2018 Plan”) reserving 2,697,085 shares for issuance to employees, consultants and directors, with the objective of securing the benefit of services for stock options rather than cash salaries.

 

In July 2019, the Board approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“2019 Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2019 Plan expire May 21, 2029.

 

In December 2020, the Board approved the introduction of the Kyto Technology and Life Science 2020 Non Qualified Stock Option Plan (“2020 Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2020 Plan expire December 16, 2030.

 

During the three months ended September 30, 2021, and September 30, 2020, the Company issued a total of 490,000 and 510,000 non-qualified stock options, respectively, to consultants and advisors vesting over terms of two years. During the corresponding six months ended September 30, 2021, and September 30, 2020, the Company issued a total of 740,000 and 630,000 non-qualified stock options, respectively.

 

 

   Number of options granted   Weighted average exercise price   Weighted average remaining life years 
Outstanding March 31, 2021   2,634,250   $0.05    8.13 
Granted   740,000    0.07    9.42 
Exercised   (18,750)   (0.03)   - 
Cancelled   -    -    - 
Outstanding September 30, 2021   3,355,500   $0.06    8.63 
                
Exercisable September 30, 2021   2,085,041   $0.04    8.90 

 

In connection with the grant of stock options the Company recognizes the value of the related option expense using the Black Scholes model, with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.

 

   September 30, 2021  

March 31, 2021

 
Stock Price at grant date  $0.07   $0.033 - $ 0.078 
Exercise Price  $0.07   $0.033 - $ 0.078 
Term in Years   0 - 2.00    0 - 2.00 
Volatility assumed   196%   71% - 196%
Annual dividend rate   0.0%   0.0%
Risk free discount rate   0.12%   0.12% - 2.0%

 

The compensation expense calculated at time of grant is recognized over the vesting period for the options granted. During the three and six months ended September 30, 2021 the Company recognized $10,897 and $21,454, respectively, as stock-based compensation expense. For the corresponding three and six months ended September 30, 2020, the Company recognized $12,805 and $13,851, respectively.

 

The intrinsic value of outstanding options at September 30, 2021 was $62,580, and $56,987 of the option expense upon grant remained unrecognized at September 30, 2021 with a remaining vesting period of 1.44 years.

 

26

 

 

D) WARRANTS

 

In conjunction with the sale of Series A Stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20 per share for a period of three years. The Company did not bifurcate the value of the warrants as the fair value of the warrant was determined to be de minimis. The Company has not issued any warrants since September, 2019. At September 30, 2021 and March 31, 2021 the fair value of the warrants was de minimis.

 

   Number of warrants   Weighted average exercise price   Weighted average remaining life in years 
Outstanding March 31, 2020   4,200,000   $1.20    2.9 
Granted   -    -    - 
Exercised   (2,603,333)  $1.20    - 
Cancelled   -    -    - 
Outstanding September 30, 2020   1,596,667   $1.20    1.4 
                
Exercisable March 31, 2020   4,200,000   $1.20    2.9 
Exercisable September 30, 2020   1,596,667   $1.20    1.4 

 

   Number  of warrants   Weighted average exercise price   Weighted average remaining life in years 
Outstanding March 31, 2021   1,596,667   $1.20    1.4 
Granted   -         - 
Exercised   -         - 
Cancelled   -         - 
Outstanding September 30, 2021   1,596,667   $1.20    1.1 
                
Exercisable March 31, 2021   1,596,667   $1.20    1.4 
Exercisable September 30, 2021   1,596,667   $1.20    1.1 

 

The Company values the warrants using the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest rate, and volatility. The assumptions used for warrant valuation were as follows:

 

Stock Price at grant date  $0.006 
Exercise Price  $1.200 
Term in Years   3.00 
Volatility assumed   73%
Annual dividend rate   0.0%
Risk free discount rate   1.79%

 

27

 

 

NOTE 7 – FINANCIAL HIGHLIGHTS

 

Per share data ( a) 

Three months

ended

  

Three months

ended

  

Six months

ended

  

Six months

ended

 
  

September 30,

2021

  

September 30,

2020

  

September 30,

2021

  

September 30,

2020

 
Net asset value  $0.82   $0.72   $0.82   $0.72 
Net investment loss  $(0.03)  $(0.03)  $(0.06)  $(0.03)
Net unrealized gain on investments  $0.10   $0.05   $0.11   $0.08 
Net increase  in net assets  $0.08   $0.05   $0.05   $0.05 
                     
Ratios and Supplemental Data                    
Net assets, end of period  $10,817,894   $4,230,731   $10,817,894   $4,230,731 
                     
Weighted average common shares outstanding, end of period   13,271,996    5,836,832    13,269,764    5,836,832 
                     
Total operating expenses/net assets   3.3%   3.8%   6.8%   4.7%
                     
Net investment loss/net assets   

3.3

%   3.8%   6.8%   4.7%
                     
Total return   9.2%   7.5%   6.1%   6.6%

 

(a)Per share data is based on the weighted average number of common shares outstanding at the end of the period.

 

NOTE 8 - SUBSEQUENT EVENTS

 

On October 5, 2021, the Company filed a Form 8-K announcing the Designation of 3,000,000 million shares of B-3 Preferred Stock. As of November 13, 2021, the Company has sold $546,000 of shares of Series B-3 Preferred Stock and invested $300,000 in three follow-on investments.

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

 

PLAN OF OPERATIONS

 

Kyto Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.

 

The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.

 

28

 

 

The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% was paid monthly from January through April 2021, and 75% was paid in subsequent months, with the balance deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in a Form 8-K on February 1, 2021, incorporated by reference herein, which was approved by the Compensation committee of the Board of Directors on that date. During the three months ended September 30, 2021, Mr. Russo received $80,000 gross pay, no consulting fees and no options were granted. During the three months ended September 30, 2020, Mr. Russo received no payroll or consulting fees, and no options were granted to him.

 

The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements, and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

 

At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non-affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).

 

As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.

 

Results of Operations

 

Revenue: In the three months and six months ended September 30, 2021 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $1,350,449 and $1,403,415 of unrealized gains from investments respectively, in these periods. In the three months and six months ended September 30, 2020 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $478,248 of unrealized gains from investments respectively, in these same periods.

.

Professional fees: In the three months and six months ended September 30, 2021, the Company reported $107,201 and $273,359, respectively, of professional fees, mainly for legal and accounting services. In the corresponding three months and six months ended September 30, 2020 the Company reported $63,605 and $76,543, respectively.

 

29

 

 

Other Operating expenses: Other operating expenses include payroll, consulting, and travel and conference fees associated with raising capital and review of investment deal-flow. In the three months and six months ended September 30, 2021, the Company incurred other operating expenses of $245,519 and $466,127, respectively. In the corresponding three months and six months ended September 30, 2020, the Company incurred other operating expenses of $96,506 and $122,936, respectively.

 

For the three months and six months ended September 30, 2021, the Company’s net increase in net assets resulting from operations was $996,133 and $662,341, respectively. For the corresponding three months and six months ended September 30, 2020, the Company’s net increase in net assets resulting from operations was $318,137 and $279,269, respectively.

 

During the three months ended September 30, 2021, the Company was subject to shelter in place regulations imposed by the State of California in mitigation of the spread of the Corona 19 virus. Since the Company does not have any dedicated office space and works virtually from the homes of its officers, there was no major disruption in working routines which continued by video and teleconference. Uncertainty arising from Covid 19 created a slow-down in the rate at which the Company was able to raise Series B funding, and thereby continue to make investments, however the Company did see a reduction in travel and investor relations expenses during the period. The Company has more than 60 discrete investments in a range of different industry and geographic segments, many of which are in the life science and medical space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future funding or do business, there have been no management reports revealing major problems and some of our portfolio companies may actually benefit from new opportunities created. We believe that our policy of spreading our investments in relatively small amounts over a large number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.

 

Liquidity and Capital Resources

 

The Company had net assets of $10,817,894 and $6,993,163 at September 30, 2021 and March 31, 2021, respectively. Cash was $316,124 and $1,437,868 at September 30, 2021 and March 31, 2021, respectively.

 

Cash from operating activities

 

The Company used net cash of $3,071,238 in operating activities during the six months ended September 30, 2021 compared to $909,564 used for the six months ended September 30, 2020. Main reasons for the higher level in 2021 were an increase in investments in portfolio companies and increased professional fees and operating expenses.

 

Cash from investing activities

 

No cash was used in investing activities.

 

Cash from financing activities

 

The Company had a net cash inflow from financing activities of $1,949,494 in the six months ended September 30, 2021 compared to $1,273,250 in the three months ended September 30, 2020. This inflow included $1,826,001 proceeds from the sale of Series B preferred stock, and $122,875 proceeds from the sale of common stock, respectively, in the six months ended September 30, 2021, compared to $1,270,000 from the sale of Series B preferred stock in the corresponding six month prior period ended September 30, 2020.

 

The Company’s plan of operations for the next twelve months is to continue to focus its efforts on finding new sources of capital by means of private placements, and to use this capital to fund additional investments as they become available, and to cover operating expenses. The Company is planning to uplift from OTC to the NASDAQ market, and raise additional funding from an initial public offering (“IPO)” for which as an initial step it has submitted an N-2 filing to the SEC for review.

 

30

 

 

CRITICAL ACCOUNTING POLICIES

 

USE OF ESTIMATES

 

In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.

 

Significant estimates at September 30, 2021 and March 31, 2021 include the valuation of investments, deferred tax assets, tax allowance, stock options and warrants.

 

INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE

 

The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their fair values. In the event that Management considers the fair value of an investment to be greater or less than the current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.

 

The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.

 

The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.

 

For investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.

 

In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.

 

The estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.

 

31

 

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

As of the date of this Quarterly Report on Form 10-Q, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

IMPACT OF INFLATION

 

The Company does not foresee any implications being created by the current rate of inflation.

 

CONTRACTUAL OBLIGATION

 

The Company has no contractual obligations outside the normal course of business with its vendors, advisors, and consultants.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting company.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the three months ended September 30, 2021 we carried out an evaluation, under the supervision and with the participation of our management, including the principal executive officer and the principal financial officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures were ineffective as of September 30, 2021. Notwithstanding this conclusion, we believe that our unaudited condensed financial statements contained in this Quarterly Report fairly present our financial position, results of operations and cash flows for the periods covered thereby in all material respects.

 

Management’s Report on Internal Control over Financial Reporting

 

With the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of September 30, 2021 based on the framework in Internal Controls—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting as of September 30, 2021 based on the COSO framework criteria. Management has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software, and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly complex and/or unusual in nature. In such instances, we seek to augment our internal accounting capabilities by obtaining assistance from third-parties who have greater expertise in such areas.

 

These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness. However, management believes that despite our material weaknesses, our financial statements for the three and six month periods ended September 30, 2021 are fairly stated, in all material respects, in accordance with US GAAP.

 

Limitations on Effectiveness of Controls and Procedures

 

Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

32

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None

 

ITEM 1A. RISK FACTORS.

 

Not required for smaller reporting company.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

The Corporation filed a certificate of Designation in April 2021 for the issue of up to 3,200,000 shares of Series B-1 Preferred stock to accredited investors under Section 4(2) or Rule 506 of Regulation D of the Securities Act 1933. As of the filing date, the Corporation had sold a total of 5,911,416 shares of Series B Preferred stock to accredited investors. The Company will use the net proceeds for investment purposes and operating expenses.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5. OTHER INFORMATION

 

None

 

ITEM 6. EXHIBITS

 

Index to Exhibits on page 13

 

33

 

 

INDEX TO EXHIBITS

 

EXHIBIT NUMBER   DESCRIPTION
     
3 (i) (a)   Articles of Incorporation of Kyto BioPharma Inc.
     
3(i) (b)   Articles of Amendment changing name to Kyto Technology and Life Science Inc *
     
3(ii)   Bylaws of Kyto Technology and Life Science Inc. **
     
3.4   Delaware incorporation and revised articles of incorporation **
     
18.1   Auditors preferability letter re adoption of ASC 946***
     
31.1   Section 302 certification of principal executive officer and principal financial & accounting officer
     
32.1   Certification pursuant to 18 USC Section 1350 adopted pursuant to section 906 of the Sarbanes Oxley Act of 2002 of the principal executive officer and principal financial accounting officer

 

* Filed as Exhibit to Company’s Form 10-SB on September 12, 2003 with the Securities and Exchange Commission.
** Previously filed with Form 8-K on July 17, 2019.
*** Filed as Exhibit with Form 10-K on July 2, 2020.

 

34

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Kyto Technology and Life Science, Inc.
     
  By: /s/ Paul Russo
   

Paul Russo

Chief Executive Officer, principal executive officer,

 

Date: November 18, 2021

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Kyto Technology and Life Science, Inc.
     
  By: /s/ Simon Westbrook
   

Simon Westbrook

Principal financial and accounting officer

 

Date: November 18, 2021

 

35